Doctor ranks his favorite GLP-1's

About this video

Gillett and O’Hara build a tier list of GLP-1 medicines as they judge them for clinical use today. Tirzepatide is their current favourite, semaglutide products rank highly but with discussion of rarer eye and gut-motility adverse events they associate with the class, while older shorter-acting and daily agents rank lower mainly on tolerability and convenience. Oral semaglutide is treated as useful, especially for diabetes, with cautions about altered absorption of other medicines. Everything not yet approved sits at the bottom regardless of promise, including the triple-agonist retatrutide, whose added glucagon activity raises growth-hormone and lean-mass questions for them, and experimental oral small molecules with high trial dropout in their telling.

Key takeaways

• Approval status and real-world safety data dominate the ranking, not headline efficacy alone
• Tolerability and dosing flexibility shape real-world usefulness, the hosts argue
• Added receptor activity is treated as added uncertainty until lean-mass and safety data arrive
• Gut slowing can change levels of other oral medicines, a point they flag for review
• Today’s lowest-ranked experimental drug could move up quickly once mature data exist

Episode details: published January 16, 2026 · 1.4K views · 18:29 long. Summary written by Self Growth Videos from the episode itself. The hormone, metabolic and peptide concepts described are Dr. Kyle Gillett’s, presented for education — not medical advice. Consult a qualified professional before changing your own health practices. Disclosure: Gillett Health is a clinical practice that treats these conditions.

← Previous: New Hair Loss Medication · Next: BPC-157 Peptide: Experts Explain What You Need to Know →

All Dr. Kyle Gillett videos · Dr. Kyle Gillett profile · Gillett Health (official site)